Screening-based discovery of drug-like O-GlcNAcase inhibitor scaffolds

FEBS Letters

Volumn 584, Issue 4, 2010, Pages 694-700

  Dorfmueller, Helge C ^a   van Aalten, Daan M F ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Crystal structure; Inhibitor; O GlcNAc; Posttranslational modification

Indexed keywords

6 N METHYLADENINE; ACETAZOLAMIDE; BETA N ACETYLHEXOSAMINIDASE; BUSPIRONE; DIPROPHYLLINE; ENZYME INHIBITOR; HYDROLASE; KETOCONAZOLE; N ACETYLGLUCOSAMINE; N ACETYLGLUCOSAMINE HYDROLASE; N ACETYLGLUCOSAMINE HYDROLASE INHIBITOR; SEMUSTINE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; IC 50; MOLECULAR WEIGHT; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY;

ADENINE; BACTERIAL PROTEINS; BETA-N-ACETYLHEXOSAMINIDASES; CATALYSIS; CATALYTIC DOMAIN; CLOSTRIDIUM PERFRINGENS; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DYPHYLLINE; ENZYME INHIBITORS; HUMANS; KINETICS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SPECTROMETRY, FLUORESCENCE;

METAZOA;

EID: 77649272310     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.12.020     Document Type: Article

References (52)

1. Torres C.R., Hart G.W. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes - evidence for O-linked GlcNAc. J. Biol. Chem. 1984, 259:3308-3317.
2. Hart G.W., Haltiwanger R.S., Holt G.D., Kelly W.G. Nucleoplasmic and cytoplasmic glycoproteins. Ciba Found. Symp. 1989, 145:102-112. di.
3. Roquemore E.P., Chevrier M.R., Cotter R.J., Hart G.W. Dynamic O-GlcNAcylation of the small heat shock protein α b-crystallin. Biochemistry 1996, 35(11):3578-3586.
4. Chou C.F., Smith A.J., Omary M.B. Characterization and dynamics of o-linked glycosylation of human cytokeratin 8 and 18. J. Biol. Chem. 1992, 267(6):3901-3906.
5. Zachara N.E., Hart G.W., signaling Cell the essential role of o-GlcNAc!. Biochim. Biophys. Acta 2006, 1761:599-617.
6. Kreppel L., Blomberg M., Hart G. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetra-tricopeptide repeats. J. Biol. Chem. 1997, 272:9308-9315.
7. Lubas W., Frank D., Krause M., Hanover J. O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. J. Biol. Chem. 1997, 272:9316-9324.
8. Jacobsen S.E., Binkowski K.A., Olszewski N.E. SPINDLY, a tetratricopeptide repeat protein involved in gibberellin signal transduction in Arabidopsis. Proc. Natl. Acad. Sci. USA 1996, 93(17):9292-9296.
9. Banerjee S., Robbins P.W., Samuelson J. Molecular characterization of nucleocytoso-lic O-GlcNAc transferases of Giardia lamblia and Cryptosporidium parvum. Glycobiology 2009, 19(4):331-336.
10. Gao Y., Wells L., Comer F.I., Parker G.J., Hart G.W. Dynamic O-glycosylation of nuclear and cytosolic proteins - cloning and characterization of a neutral, cytosolic β-N-acetylglucosaminidase from human brain. J. Biol. Chem. 2001, 276:9838-9845.
11. Comtesse N., Maldener E., Meese E. Identification of a nuclear variant of MGEA5, a cytoplasmic hyaluronidase and a β-N-acetylglucosaminidase. Biochem. Biophys. Res. Commun. 2001, 283(3):634-640.
12. Dong D.L.Y., Hart G.W. Purification and characterization of an O-GlcNAc selective N-acetyl-β-d-glucosaminidase from rat spleen cytosol. J. Biol. Chem. 1994, 269:19321-19330.
13. Kelly W.G., Hart G.W. Glycosylation of chromosomal proteins: localization of O-linked N-acetylglucosamine in Drosophila chromatin. Cell 1989, 57(2):243-251.
14. Forsythe M.E., Love D.C., Lazarus B.D., Kim E.J., Prinz W.A., Ashwell G., Krause M.W., Hanover J.A. Caenorhabditis elegans ortholog of a diabetes susceptibility locus: oga-1 (o-GlcNAcase) knockout impacts o-GlcNAc cycling, metabolism, and dauer. Proc. Natl. Acad. Sci. USA 2006, 103:11952-11957.
15. Wells L., Vosseller K., Hart G.W. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 2001, 291(5512):2376-2378.
16. Love D.C., Hanover J.A. The hexosamine signaling pathway: deciphering the " O-GlcNAc code" Sci. STKE 2005, 312:1-14.
17. Hart G.W., Housley M.P., Slawson C. Cycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 2007, 446:1017-1022.
18. Haltiwanger R.S., Grove K., Philipsberg G.A. Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-β-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-d-glucopyranosylidene)amino-N-phenylcarbamate. J. Biol. Chem. 1998, 273:3611-3617.
19. Liu K., Paterson A.J., Chin E., Kudlow J.E. Glucose stimulates protein modification by o-linked GlcNAc in pancreatic β cells: linkage of o-linked GlcNAc to β cell death. Proc. Natl. Acad. Sci. USA 2000, 97:2820-2825.
20. Macauley M.S., Whitworth G.E., Debowski A.W., Chin D., Vocadlo D.J. O-GlcNAcase uses substrate-assisted catalysis - kinetic analysis and development of highly selective mechanism-inspired inhibitors. J. Biol. Chem. 2005, 280:25313-25322.
21. Horsch M., Hoesch L., Vasella A., Rast D.M. N-acetylglucosaminono-1,5-lactone oxime and the corresponding (phenylcarbamoyl)oxime - novel and potent inhibitors of β-N-acetylglucosaminidase. Eur. J. Biochem. 1991, 197:815-818.
22. Knapp S., Vocadlo D., Gao Z., Kirk B., Lou J., Withers S.G. NAG-thiazoline, an N-acetyl-β-hexosaminidase inhibitor that implicates acetamido participation. J. Am. Chem. Soc. 1996, 118:6804-6805.
23. Cetinbas N., Macauley M.S., Stubbs K.A., Drapala R., Vocadlo D.J. Identification of asp174 and asp175 as the key catalytic residues of human o-glcnacase by functional analysis of site-directed mutants. Biochemistry 2006, 45(11):3835-3844.
24. Rao F.V., Dorfmueller H.C., Villa F., Allwood M., Eggleston I.M., van Aalten D.M.F. Structural insights into the mechanism and inhibition of eukaryotic O-GlcNAc hydrolysis. EMBO J. 2006, 25:1569-1578.
25. Dennis R.J., Taylor E.J., Macauley M.S., Stubbs K.A., Turkenburg J.P., Hart S.J., Black G.N., Vocadlo D.J., Davies G.J. Structure and mechanism of a bacterial β-glucosaminidase having O-GlcNAcase activity. Nat. Struct. Mol. Biol. 2006, 13:365-371.
26. Stubbs K.A., Balcewich M., Mark B.L., Vocadlo D.J. Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC mediated β-lactam resistance. J. Biol. Chem. 2007.
27. Ficko-Blean E., Stubbs K.A., Nemirovsky O., Vocadlo D.J., Boraston A.B. Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB. Proc. Natl. Acad. Sci. USA 2008, 105(18):6560-6565.
28. Macauley M.S., Bubb A.K., Martinez-Fleites C., Davies G.J., Vocadlo D.J. Elevation of global O-GlcNAc levels in 3T3-L1 adipocytes by selective inhibition of O-GlcNAcase does not induce insulin resistance. J. Biol. Chem. 2008, 283(50):34687-34695.
29. Junod A., Lambert A.E., Orci L., Pictet R., Gonet A.E., Renold A.E. Studies of the diabetogenic action of streptozotocin. Proc. Soc. Exp. Biol. Med. 1967, 126(1):201-205.
30. Bennett R.A., Pegg A.E. Alkylation of DNA in rat tissues following administration of streptozotocin. Cancer Res. 1981, 41(7):2786-2790.
31. Pathak S., Dorfmueller H.C., Borodkin V.S., Van Aalten D.M.F. Chemical dissection of the link between streptozotocin, O-GlcNAc, and pancreatic cell death. Chem. Biol. 2008, 15:799-807.
32. Kroncke K.D., Fehsel K., Sommer A., Rodriguez M.L., Kolb-Bachofen V. Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotozin contributes to islet cell DNA damage. Biol. Chem. Hoppe-Seyler 1995, 376(3):179-185.
33. Mansford K.R., Opie L. Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet 1968, 1:670-671.
34. Gao Y., Parker G.J., Hart G.W. Streptozotocin-induced β-cell death is independent of its inhibition of O-GlcNAccase in pancreatic min6 cells. Arch. Biochem. Biophys. 2000, 383:296-302.
35. Kaneto H., Xu G., Song K.H., Suzuma K., Bonner-Weir S., Sharma A., Weir G.C. Activation of the hexosamine pathway leads to deterioration of pancreatic β-cell function through the induction of oxidative stress. J. Biol. Chem. 2001, 276:31099-31104.
36. Okuyama R., Yachi M. Cytosolic O-GlcNAc accumulation is not involved in β-cell death in HIT-T15 or Min6. Biochem. Biophys. Res. Commun. 2001, 287:366-371.
37. Ficko-Blean E., Gregg K.J., Adams J.J., Hehemann J.-H., Czjzek M., Smith S.P., Boraston A.B. Portrait of an enzyme, a complete structural analysis of a multimodular beta-N-acetylglucosaminidase from Clostridium perfringens. J. Biol. Chem. 2009, 284(15):9876-9884.
38. Yuzwa S., Macauley M., Heinonen J., Shan X., Dennis R., He Y., Whitworth G., Stubbs K., McEachern E., Davies G., Vocadlo D. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat. Chem. Biol. 2008, 4:483-490.
39. Dorfmueller H.C., Borodkin V.S., Schimpl M., Shepherd S.M., Shpiro N.A., van Aalten D.M.F. GlcNAcstatin: a picomolar, selective O-GlcNAcase inhibitor that modulates intracellular O-GlcNAcylation levels. J. Am. Chem. Soc. 2006, 128:16484-16485.
40. Dorfmueller H.C., Borodkin V.S., Schimpl M., van Aalten D.M.F. GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation. Biochem. J. 2009, 420(2):221-227.
41. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44:235-249.
42. Rao F.V., Andersen O.A., Vora K.A., DeMartino J.A., van Aalten D.M.F. Methylxanthine drugs are chitinase inhibitors: investigation of inhibition and binding modes. Chem. Biol. 2005, 12:973-980.
43. Schuettelkopf A.W., Andersen O.A., Rao F.V., Allwood M., Lloyd C., Eggleston I.M., van Aalten D.M.F. J. Biol. Chem. 2006, 281:27278-27285.
44. Kuntz I.D., Chen K., Sharp K.A., Kollman P.A. The maximal affinity of ligands. Proc. Nat. Acad. Sci. USA 1999, 96:9997-10002.
45. Hopkins A.L., Groom C.R., Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 2004, 9:430-431.
46. Abad-Zapatero C., Metz J.T. Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today 2005, 10(7):464-469.
47. Rao F.V., Houston D.R., Boot R.G., Aerts J.M.F.G., Hodkinson M., Adams D.J., Sh-iomi K., Omura S., van Aalten D.M.F. Specificity and affinity of natural product cyclopentapeptide inhibitors against A. fumigatus, human, and bacterial chitinases. Chem. Biol. 2005, 12:65-76.
48. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276:307-326.
49. Schuettelkopf A.W., van Aalten D.M.F. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Cryst. 2004, D60:1355-1363.
50. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Cryst. 2004, D60:2126-2132.
51. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Cryst. 1997, D53:240-255.
52. Leatherbarrow R.J. GraFit. Version 5 2001, Erithacus Software Ltd., Horley, U.K.